Publications by authors named "Francisco Javier Ramos Pascual"
Clin Cancer Res
April 2010
Article Synopsis
- Irinotecan is a common treatment for colorectal cancer but only 20-30% of patients respond positively, highlighting the need for biomarkers to predict patient outcomes.
- Researchers conducted a study identifying aprataxin (APTX) as a potential biomarker linked to irinotecan sensitivity by analyzing colorectal cancer cell lines and patient tumor samples.
- High levels of aprataxin in tumors were associated with poorer survival outcomes, indicating that low aprataxin levels could help identify patients who may benefit more from alternative therapies instead of irinotecan.
